CLAIMS

1. A compound of the formula



(I)

wherein R^1 is $(C_1\text{-}C_6)$alkyl, optionally substituted by $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl, wherein each of said $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, $(C_1\text{-}C_6)$alkyl, $HO(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-NH(C=O)-, $NH_2(C=O)$-, $(C_1\text{-}C_6)$alkoxy, or $(C_3\text{-}C_{10})$cycloalkyl, wherein said $(C_3\text{-}C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1\text{-}C_6)$alkyl-;

R^2 is hydrogen, halogen, -CN, and $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $-CF_3$, CF_3O-, $(C_1\text{-}C_6)$alkyl-NH-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-(S=O)-, $(C_1\text{-}C_6)$alkyl-(SO_2)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, formyl, $(C_1\text{-}C_6)$alkyl-(C=O)-, and $(C_3\text{-}C_6)$cycloalkyl; and

R^3 is a suitably substituted nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of the formula:



II

or



III

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

2. A compound of the formula



(I)

wherein R^1 is $(C_1\text{-}C_6)$alkyl, optionally substituted by $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl, wherein each of said $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, $(C_1\text{-}C_6)$alkyl, $HO(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-NH(C=O)-, $NH_2(C=O)$-, $(C_1\text{-}C_6)$alkoxy, or $(C_3\text{-}C_{10})$cycloalkyl, wherein said $(C_3\text{-}C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1\text{-}C_6)$alkyl-;

R^2 is hydrogen, halogen, -CN, and $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $-CF_3$, CF_3O-, $(C_1\text{-}C_6)$alkyl-NH-, $[(C_1\text{-}C_6)\text{alkyl}]_2\text{-N-}$, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-(S=O)-, $(C_1\text{-}C_6)$alkyl-(SO_2)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, formyl, $(C_1\text{-}C_6)$alkyl-(C=O)-, and $(C_3\text{-}C_6)$cycloalkyl;

R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of the formula:



IV or V

wherein R^4 and R^5 are independently selected from the group of suitable substituents, such as hydrogen, halo, hydroxy, -CN, $HO\text{-}(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted with one to three fluoro, $(C_1\text{-}C_6)$alkoxy optionally substituted with one to three fluoro, HO_2C-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $R^6R^8N(O_2S)$-, $(C_1\text{-}C_6)$alkyl-(O_2S)-NH-, $(C_1\text{-}C_6)$alkyl-O_2S-$[(C_1\text{-}C_6)\text{alkyl-N}]$-, $R^6R^8N(C=O)$-, $R^6R^8N(CH_2)_m$-, $(C_6\text{-}C_{10})$aryl, $(C_3\text{-}C_8)$cycloalkyl, $(C_1\text{-}C_{10})$heteroaryl, $(C_1\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl-O-, $(C_3\text{-}C_8)$cycloalkyl-O-, $(C_1\text{-}C_{10})$heteroaryl-O- and $(C_1\text{-}C_{10})$heterocyclyl-O-; and

R^7 is independently selected from the group of suitable substituents such as hydrogen and $(C_1\text{-}C_6)$alkyl optionally substituted with one to three halogens, hydroxy, -CN, $(C_1\text{-}C_6)$alkoxy-, $(C_2\text{-}C_6)$alkenoxy, $(C_1\text{-}C_6)$alkyl-SO_2-, NH_2-, $((C_1\text{-}C_6)\text{alkyl})_n\text{-N-}$, $((C_2\text{-}C_6)\text{alkenyl})_n\text{-N-}$, $((C_2\text{-}C_6)\text{alkynyl})_n\text{-N-}$, $NH_2(C=O)$-, $(C_1\text{-}C_6)$alkyl-(C=O)N-, $((C_1\text{-}C_6)\text{alkyl})_n\text{-N-(C=O)-}$, $(C_2\text{-}C_6)$alkenyl-(C=O)N-, $((C_2\text{-}C_6)\text{alkenyl})_n\text{-N-(C=O)-}$, $(C_2\text{-}C_6)$alkynyl-(C=O)N-, $((C_2\text{-}C_6)\text{alkynyl})_n\text{-N-(C=O)-}$, $(C_1\text{-}C_6)$alkyl-(C=O)-, $(C_2\text{-}C_6)$alkenyl-(C=O)-, $(C_2\text{-}C_6)$alkynyl-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, $((C_1\text{-}C_{10})$heterocyclyl-(C=O)-, $(C_6\text{-}C_{10})$aryl-(C=O), $(C_1\text{-}C_{10})$heteroaryl-(C=O), $(C_1\text{-}C_6)$alkyl-(C=O)O-, $(C_2\text{-}C_6)$alkenyl-(C=O)O-, $(C_2\text{-}C_6)$alkynyl-(C=O)O-, $(C_1\text{-}C_6)$alkyl-O(C=O)-,

$(C_2\text{-}C_6)$alkenyl-O-(C=O)-, $(C_2\text{-}C_6)$alkynyl-O-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, and $(C_1\text{-}C_{10})$heteroaryl;

wherein R^4, R^5 and R^7 may each be optionally substituted on any aliphatic or aromatic carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $-CF_3$, CF_3O-, $(C_1\text{-}C_6)$alkyl-NH-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-(S=O)-, $(C_1\text{-}C_6)$alkyl-(SO_2)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, formyl, $(C_1\text{-}C_6)$alkyl-(C=O)-, and $(C_3\text{-}C_6)$cycloalkyl;

R^6 and R^8 are each independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, HO-$(C_2\text{-}C_6)$alkyl and $(C_3\text{-}C_8)$cycloalkyl, or R^6 and R^8 may optionally be taken together with the nitrogen atom to which they are attached to form a 3 to 8 membered heterocycle;

n is an integer from zero to two; and

m is an integer from one to two;

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

3. A compound of any of the preceding claims wherein R^2 is chloro, methyl or ethyl.

4. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV):



(IV)

R^4 is hydrogen or methyl,

and R^7 is selected from the group consisting of:



5. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is



6. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from the group consisting of:



7. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is



8. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from:



9. A compound of any of the preceding claims wherein R^3 is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), R^4 is hydrogen or methyl, and R^7 is selected from:



10. A compound selected from the group consisting of:

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-5-(4-cyanomethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-N-(1-hydroxy-cycloheptyl methyl)-benzamide;

2-Chloro-N-(1-hydroxy-3,3-dimethyl-cyclohexylmethyl)-5-(3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-benzamide;

5-(4-Carbamoylmethyl-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl)-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

5-[4-(2-Amino-ethyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-methyl-propyl)-3-methyl-5-oxo-4,5-dihydro-[1,2,4]triazol-1-yl]-benzamide.

11. A pharmaceutical composition for treating a IL-1 mediated disease in a mammal in need thereof, comprising a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

12. A method of treating a IL-1 mediated disease in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof.